Project Grant R21AI185489
Award Date
6/23/25
Completion Date
5/31/27
Dollars Obligated
$427K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $155,227 to The Johns Hopkins University to generate proof-of-concept data on a novel strategy to treat Mycobacterium abscessus (MAB) chronic lung disease. The project aims to investigate whether a monoclonal antibody (CMTX-101) can effectively disrupt MAB biofilms in the lungs, which could enhance the efficacy of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $466,725 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of South Carolina. The 5-year grant, effective June 1, 2025 through May 31, 2030, will enhance the utility of deer mice as an infectious disease model. Specifically, the funding will: (1) strengthen the breeding capacity of the university's Peromyscus Genetic Stock Center, (2) develop Peromyscus-specific...
This Project Grant award of $750,815, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research aimed at developing novel anti-infective strategies to treat pulmonary mucormycosis, a deadly invasive fungal infection. The key objectives are to: 1) examine the role of the host cell hypoxia-response pathway, specifically the protein ANGPTL4, in the pathogenesis of mucormycosis and explore its therapeutic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $162,000 in funding to The Washington University to conduct research on the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to characterize pDC function during MTB infection to identify potential pDC-specific therapeutic targets that could lead to host-directed...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $451,000.00 to The University of Texas Southwestern Medical Center to develop an "Alveolus on a Chip Model of Non-Tuberculous Mycobacteria Infection". The project aims to leverage a human lung-on-a-chip model to gain insights into the pathogenesis of non-tuberculous mycobacteria (NTM) infections and...
This Project Grant award for $862,440.00 was made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the development and evaluation of a new humanized mouse model to study gene editing therapies targeting chronic hepatitis B virus (HBV) infection. The key objectives are to: 1) Evaluate the anti-HBV efficacy of HBV gene therapy in liver-humanized NSG-PIZ mice, including assessing...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $895,538 to HMH Hospitals Corporation, doing business as Hackensack University Medical Center, for a research project titled "Shorter and More Effective Oral Regimens for M. abscessus Pulmonary Disease". The primary objectives are to discover all-oral drug regimens, either using FDA-approved agents or novel preclinical/clinical...
This $246,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to investigate the role of lung repair and regeneration pathways in tuberculosis (TB). The award aims to determine the functional role of the bone morphogenetic protein (BMP) signaling pathway in TB control and reactivation, as well as characterize the cellular mechanisms of BMP pathway activation during TB...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding will support a 2-year developmental project at the University of California, Irvine to advance immunological research tools for studying the white-footed deermouse (Peromyscus leucopus), a natural reservoir for zoonotic agents like Lyme disease, anaplasmosis, and...